Granted Patent
B2
US 12,414,934 · App. 17/202,755 · Granted Sep 16, 2025
Combination therapies
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
Claims (17)
1. A method of treating a cancer that is prostate cancer, pancreatic cancer, leukemia, lymphoma, ovarian cancer, neuroblastoma, glioblastoma, kidney cancer, bladder cancer, gastrointestinal stromal tumors, liver cancer, head and neck cancer, lung cancer, melanoma, or a hematological malignancy, comprising administering to a subject in need thereof an effective amount of
(i) an angiogenesis inhibitor; and
(ii) 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5).
2. The method of claim 1 , wherein the angiogenesis inhibitor is nintedanib, bevacizumab, sorafenib, sunitinib, thalidomide, dovitinib, regorafenib, or imatinib.
3. The method of claim 1 , wherein the angiogenesis inhibitor is nintedanib.
4. The method of claim 1 , wherein the angiogenesis inhibitor is bevacizumab.
5. The method of claim 1 , wherein the cancer is ovarian cancer, kidney cancer, liver cancer, or lung cancer.
6. The method of claim 1 , wherein the cancer is lung cancer.
7. The method of claim 1 , wherein the cancer is refractory, non-responsive, or resistant to chemotherapy and/or haploidentical stem cell transplantation.
8. The method of claim 7 , wherein the cancer is non-responsive or resistant to the angiogenesis inhibitor.
9. The method of claim 1 , wherein the angiogenesis inhibitor and 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5) are administered simultaneously or sequentially.
10. A method of treating a chemoresistant cancer that is prostate cancer, pancreatic cancer, leukemia, lymphoma, ovarian cancer, neuroblastoma, glioblastoma, kidney cancer, bladder cancer, gastrointestinal stromal tumors, liver cancer, head and neck cancer, lung cancer, melanoma, or a hematological malignancy, comprising administering to a subject in need thereof an effective amount of
(i) an angiogenesis inhibitor; and
(ii) 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5).
11. The method of claim 10 , wherein the chemoresistant cancer is ovarian cancer, kidney cancer, liver cancer, or lung cancer.
12. The method of claim 10 , wherein the chemoresistant cancer is resistant to the angiogenesis inhibitor.
13. The method of claim 10 , wherein the angiogenesis inhibitor is nintedanib.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 27, 2024
From: MEI PHARMA, INC
To: AARDVARK THERAPEUTICS, INC.
Reel/Frame 069422/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 16, 2021
From: GOLD, DANIEL P.
To: MEI PHARMA, INC.
Reel/Frame 055605/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 16, 2021
From: QUINTELA-FANDINO, MIGUEL
To: THE SPANISH NATIONAL CANCER RESEARCH CENTRE
Reel/Frame 055606/0214 →
Continuity (3)
Division
15546900
Provisional Application
62111030
· Feb 2, 2015
References Cited (357)
US 3340276A
· Carney et al.
· 1967
[cited by applicant]
US 3471520A
· Klaus et al.
· 1969
[cited by applicant]
US 3535344A
· Klaus et al.
· 1970
[cited by applicant]
US 4157984A
· Zilliken
· 1979
[cited by applicant]
US 4218489A
· Zilliken
· 1980
[cited by applicant]
US 4232122A
· Zilliken
· 1980
[cited by applicant]
US 4234577A
· Zilliken
· 1980
[cited by applicant]
US 4366082A
· Zilliken
· 1982
[cited by applicant]
US 4366248A
· Zilliken
· 1982
[cited by applicant]
US 4368264A
· Zilliken
· 1983
[cited by applicant]
US 4390559A
· Zilliken
· 1983
[cited by applicant]
US 4447622A
· Salman et al.
· 1984
[cited by applicant]
US 4644012A
· Tsuda et al.
· 1987
[cited by applicant]
US 4814346A
· Albert et al.
· 1989
[cited by applicant]
US 5024998A
· Bodor
· 1991
[cited by applicant]
US 5059609A
· Eggler et al.
· 1991
[cited by applicant]
US 5134127A
· Stella et al.
· 1992
[cited by applicant]
US 5280040A
· Labroo et al.
· 1994
[cited by applicant]
US 5376645A
· Stella et al.
· 1994
[cited by applicant]
US 5389646A
· Labroo
· 1995
[cited by applicant]
US 5464862A
· Labroo et al.
· 1995
[cited by applicant]
US 5696149A
· Korsgaard et al.
· 1997
[cited by applicant]
US 5726202A
· Shalmi et al.
· 1998
[cited by applicant]
US 5756539A
· Skrumsager et al.
· 1998
[cited by applicant]
US 5780503A
· Biftu et al.
· 1998
[cited by applicant]
US 5849461A
· Hatakeyama et al.
· 1998
[cited by applicant]
US 5874418A
· Stella et al.
· 1999
[cited by applicant]
US 5883118A
· Shalmi et al.
· 1999
[cited by applicant]
US 5919817A
· Jacobsen et al.
· 1999
[cited by applicant]
US 5958967A
· Jacobsen et al.
· 1999
[cited by applicant]
US 5985306A
· Jacobsen et al.
· 1999
[cited by applicant]
US 5994390A
· Jacobsen et al.
· 1999
[cited by applicant]
US 5998451A
· Eggler et al.
· 1999
[cited by applicant]
US 6005003A
· Nique
· 1999
[cited by applicant]
US 6043269A
· Jacobsen et al.
· 2000
[cited by applicant]
US 6316494B1
· Jacobsen et al.
· 2001
[cited by applicant]
US 6479467B1
· Buchanan et al.
· 2002
[cited by applicant]
US 6509323B1
· Davis
· 2003
[cited by applicant]
US 6528042B1
· Brown et al.
· 2003
[cited by applicant]
US 6610671B2
· Buchanan et al.
· 2003
[cited by applicant]
US 6610733B2
· Park et al.
· 2003
[cited by applicant]
US 6645951B1
· Jo et al.
· 2003
[cited by applicant]
US 6649648B1
· Kelly et al.
· 2003
[cited by applicant]
US 6660804B1
· Weltrowski et al.
· 2003
[cited by applicant]
US 7056952B1
· Joannou
· 2006
[cited by applicant]
US 7202273B2
· Kelly et al.
· 2007
[cited by applicant]
US 7601855B2
· Heaton et al.
· 2009
[cited by applicant]
US 7906554B2
· Kelly et al.
· 2011
[cited by applicant]
US 8080675B2
· Heaton et al.
· 2011
[cited by applicant]
US 8084628B2
· Heaton et al.
· 2011
[cited by applicant]
US 8163795B2
· Heaton et al.
· 2012
[cited by applicant]
US 8461361B2
· Heaton et al.
· 2013
[cited by applicant]
US 8697891B2
· Heaton et al.
· 2014
[cited by applicant]
US 8957109B2
· Heaton et al.
· 2015
[cited by applicant]
US 9138478B2
· Heaton et al.
· 2015
[cited by applicant]
US 9198895B2
· Heaton et al.
· 2015
[cited by applicant]
US 9381186B2
· Heaton et al.
· 2016
[cited by applicant]
US 9663484B2
· Jeoffreys et al.
· 2017
[cited by applicant]
US 9708283B2
· Moreno
· 2017
[cited by applicant]
US 9981936B2
· Moreno
· 2018
[cited by applicant]
US 20020128468A1
· Buchanan et al.
· 2002
[cited by applicant]
US 20040063663A1
· Buchanan et al.
· 2004
[cited by applicant]
US 20040209825A1
· Lahey et al.
· 2004
[cited by applicant]
US 20060167037A1
· Kelly et al.
· 2006
[cited by applicant]
US 20060167083A1
· Kelly
· 2006
[cited by applicant]
US 20080014249A1
· Heaton et al.
· 2008
[cited by applicant]
US 20080069900A1
· Kelly et al.
· 2008
[cited by applicant]
US 20100130598A1
· Brown et al.
· 2010
[cited by applicant]
US 20100152284A1
· Brown et al.
· 2010
[cited by applicant]
US 20100173983A1
· Brown et al.
· 2010
[cited by applicant]
US 20120039917A1
· Husband et al.
· 2012
[cited by applicant]
US 20120251630A1
· Alvero et al.
· 2012
[cited by applicant]
US 20140093498A1
· Gschwind et al.
· 2014
[cited by applicant]
US 20160136129A1
· Heaton et al.
· 2016
[cited by applicant]
US 20160287555A1
· Heaton et al.
· 2016
[cited by applicant]
US 20190142790A1
· Jeoffreys et al.
· 2019
[cited by applicant]
US 20230145478A1
· Jeoffreys et al.
· 2023
[cited by applicant]
CA 2581316A1
· 2006
[cited by applicant]
CA 2641541A1
· 2010
[cited by applicant]
EP 0267155A2
· 1988
[cited by applicant]
EP 0313295A2
· 1989
[cited by applicant]
EP 0470310A1
· 1992
[cited by applicant]
EP 0955286A1
· 1999
[cited by applicant]
EP 3253208A1
· 2017
[cited by applicant]
GB 1433013A
· 1976
[cited by applicant]
JP 2000506507A
· 2000
[cited by applicant]
JP 2001502706A
· 2001
[cited by applicant]
JP 2001502711A
· 2001
[cited by applicant]
JP 2002529372A
· 2002
[cited by applicant]
JP 2003508526A
· 2003
[cited by applicant]
JP 2005504796A
· 2005
[cited by applicant]
JP 2005528391A
· 2005
[cited by applicant]
JP 2006096734A
· 2006
[cited by applicant]
JP 2008513376A
· 2008
[cited by applicant]
JP 2012144537A
· 2012
[cited by applicant]
JP 2013541563A
· 2013
[cited by applicant]
JP 2014237638A
· 2014
[cited by applicant]
WO WO8002098A1
· 1980
[cited by applicant]
WO WO9408986A1
· 1994
[cited by applicant]
WO WO9420099A1
· 1994
[cited by applicant]
WO WO9621442A1
· 1996
[cited by applicant]
WO WO9621443A1
· 1996
[cited by applicant]
WO WO9621444A1
· 1996
[cited by applicant]
WO WO9622091A1
· 1996
[cited by applicant]
WO WO9622092A1
· 1996
[cited by applicant]
WO WO9622093A1
· 1996
[cited by applicant]
WO WO9725035A1
· 1997
[cited by applicant]
WO WO9725036A1
· 1997
[cited by applicant]
WO WO9725037A1
· 1997
[cited by applicant]
WO WO9725038A1
· 1997
[cited by applicant]
WO WO9802154A1
· 1998
[cited by applicant]
WO WO9802156A1
· 1998
[cited by applicant]
WO WO9808503A1
· 1998
[cited by applicant]
WO WO9817662A1
· 1998
[cited by applicant]
WO WO9818770A1
· 1998
[cited by applicant]
WO WO9818771A1
· 1998
[cited by applicant]
WO WO9818772A1
· 1998
[cited by applicant]
WO WO9818773A1
· 1998
[cited by applicant]
WO WO9818774A1
· 1998
[cited by applicant]
WO WO9818775A1
· 1998
[cited by applicant]
WO WO9818776A1
· 1998
[cited by applicant]
WO WO9818778A1
· 1998
[cited by applicant]
WO WO9818779A1
· 1998
[cited by applicant]
WO WO9825916A1
· 1998
[cited by applicant]
WO WO9832437A1
· 1998
[cited by applicant]
WO WO9833499A1
· 1998
[cited by applicant]
WO WO9833500A1
· 1998
[cited by applicant]
WO WO9936050A1
· 1999
[cited by applicant]
WO WO9949862A1
· 1999
[cited by applicant]
WO WO9955898A1
· 1999
[cited by applicant]
WO WO9963974A2
· 1999
[cited by applicant]
WO WO9965893A1
· 1999
[cited by applicant]
WO WO0049009A1
· 2000
[cited by applicant]
WO WO0066576A1
· 2000
[cited by applicant]
WO WO0107031A1
· 2001
[cited by applicant]
WO WO0117986A1
· 2001
[cited by applicant]
WO WO0126651A2
· 2001
[cited by applicant]
WO WO0154699A1
· 2001
[cited by applicant]
WO WO0202548A1
· 2002
[cited by applicant]
WO WO02059113A1
· 2002
[cited by applicant]
WO WO03016270A2
· 2003
[cited by applicant]
WO WO03035635A1
· 2003
[cited by applicant]
WO WO03063859A1
· 2003
[cited by applicant]
WO WO03086386A1
· 2003
[cited by applicant]
WO WO2004030662A1
· 2004
[cited by applicant]
WO WO2005049008A1
· 2005
[cited by applicant]
WO WO2005049627A1
· 2005
[cited by applicant]
WO WO2006032085A1
· 2006
[cited by applicant]
WO WO2006032086A1
· 2006
[cited by applicant]
WO WO2008052256A1
· 2008
[cited by applicant]
WO WO2008113100A1
· 2008
[cited by applicant]
WO WO2010022467A1
· 2010
[cited by applicant]
WO WO2010045674A1
· 2010
[cited by applicant]
WO WO2012061409A1
· 2012
[cited by applicant]
WO WO2012061413A2
· 2012
[cited by applicant]
WO WO2015117202A1
· 2015
[cited by applicant]
WO WO2016126618A1
· 2016
[cited by applicant]
Abegaz et al.: Isoflavonoids from the roots of Salsola somalensis. Phytochemistry. 30(4):1281-4, 1991 (Abstract Only in English).
[cited by applicant]
Agarwal et al.: Isoflavones of two Iris species. Phytochemistry (Elsevier) 23(11):2703-4, 1984. (Abstract Only in English).
[cited by applicant]
Agarwal et al.: Phenolic constituents of Iris Milesii rhizomes, Phytochemistry (Elsevier) 23(6):1342-3, 1984. (Abstract Only in English).
[cited by applicant]
Aggarwal et al.: From chemoprevention to chemotherapy: common targets and common goals. Expert Opin. Investig. Drugs. 2004;13(10):1327-38.
[cited by applicant]
Akimoto et al.: Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int. J. Radi…
[cited by applicant]
ALDRICH Handbook of Fine Chemicals and Laboratory Equipment © 2002, Sigma-Aldrich Pty Limited, Australia: Note: Sigma-Aldrich is a US Company, catalogue/handbook from which the pages derive from is the AU publication.
[cited by applicant]
Alvero AB, Brown D, Montagna M, Matthews M, Mor G. (2007) Phenoxodiol-Topotecan Co-5 Administration Exhibit Significant Anti-Tumor Activity Without Major Adverse Side Effects. Cancer Biol Ther. 6:612-7.
[cited by applicant]
Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G. (2008) Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol. 4(4):475-82.
[cited by applicant]
Antus et al.: Synthesis of some pterocarpenes obtained from Brya ebenus, J. Chem. Soc., Perkin Trans. 6:1389-94, 1982 (Abstract Only in English).
[cited by applicant]
Arnone et al.: Isoflavonoid constituents of the West African red wood,
[cited by applicant]
Bartelink et al. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 38(2):216-222 (2002).
[cited by applicant]
Bellisarii et al.: Tumor necrosis factor-α and cardiovascular diseases. Ital Heart J. 2001;2(6):408-17.
[cited by applicant]
Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).
[cited by applicant]
Berridge MV, Tan AS. (1998) Trans-plasma membrane electron transport a cellular assay for NADH- and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplas…
[cited by applicant]
Bundgaard. Design and Application of Prodrugs. Textbook of Drug Design and Development. Krosgaard-Larsen and Bundgaard. Chapter 5. pp. 113-191 (1991).
[cited by applicant]
Bundgaard. Design of Prodrugs. Elsevier (12 pgs.) (1985).
[cited by applicant]
Bundgaard. Means to Enhance Penetration: Prodrugs as a Means to Improve the Delivery of Peptide Drugs. Advanced Drug Delivery Review 8:1-38 (1992).
[cited by applicant]
Bury et al.: Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem. 2002;10:125-145.
[cited by applicant]
Caltagirone et al.: Flavanoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer Suppl. 87(4):595-600, 2002. (Abstract Only in English).
[cited by applicant]
Caltagirone et al.: Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer, American Journal of Respiratory Cell and Molecular Biolo…
[cited by applicant]
Challa, et al. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. Oct. 14, 2005;6(2):E329-357. doi: 10.1208/pt060243.
[cited by applicant]
Constantinou et al.: Phenoxodiol (2H-1-Benzopyran-7-0, 1, 3-(4-hydroxyphenyl), a Novel Isoflavone Derivative, Inhibits DNA Topoisomerase II by Stabilizing the Cleavable Complex. Anticancer Research. 2002;22:2581-86.
[cited by applicant]
Constantinou et al.: Phenoxodiol, a novel isofavone derivative, inhibits dimethylbenz[a]anthracene(DMBA)-induced mammary carcinogenesis in female Sprague—Dawley rats. Eur J Cancer. 2003; 39:1012-18.
[cited by applicant]
De Vincenzo et al.:Flavanoids and negative control of cell proliferation in ovarian tumors. Acta Medica Romana. 30(1-2):126-32, 1992. (Abstract Only in English).
[cited by applicant]
Dorai, et al , Role of chemopreventive agents in cancer therapy. Cancer Lett. 215:129-40, 2004.
[cited by applicant]
Ettmayer et al., Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, vol. 47, No. 10, pp. 2394-2404 (2004).
[cited by applicant]
Fukui et al.: The synthesis of irisolone, Bull. Chem. Soc. Japan. 38(6):887-93, 1965 (Abstract Only in English).
[cited by applicant]
Gamble et al.: Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer. 118:2412-20, 2006.
[cited by applicant]
Giacomelli et al., Silybin and its bioavailable, phospholipid complex(IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sciences. Feb. 8, 2002; 70(12):1447-59 (Abstract Only in English).
[cited by applicant]
Gokmen-Polar et al.: Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. Journal of Cancer. 5(8):533-645 (2014).
[cited by applicant]
Gupta et al., The use of Friedel-Crafts reactions for the synthesis of deoxybenzoins. Indian J Chem. 1968; 6(9):481-4 (Abstract Only in English).
[cited by applicant]
Hem Chandra Jha et al.: Carbon-13-chemical shift assignments of chromones and isoflavones. Can J Chem. 58:1211-19, 1980.
[cited by applicant]
Hersey et al.: How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer. Nov. 2001; 1(2)142-50.
[cited by applicant]
Horie et al.: Studies of the selective O-alkylation and dealkylation of flavonoids. XX. A convenient method for synthesizing 5,6,7-trihydroxyisoflavones and 5,6-dihydroxy-7-methoxyisoflavones. Pharm Bull. 44(3):486-91, …
[cited by applicant]
Hu et al., Identification of CYP1A2 as the main isoform for the Phase 1 hydroxylated metabolism of genistein and a prodrug converting exzyme of methylated isoflavones. Drug Metabolism and Dispostion, 31(7):924-931, 2003.
[cited by applicant]
Caltagirone et al.: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Can, 2000, 87(4), pp. 595-600.
[cited by applicant]
Ito et al.: Isoflavonoids from Belamcanda chinensis. Pharm Bull. 49(9):1229-31, 2001 (Abstract Only in English).
[cited by applicant]
Kakeji et al.: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs. 15:39-48, 1997.
[cited by applicant]
Kamsteeg et al.: Phenoxodiol—an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 22:2611-20, 2003.
[cited by applicant]
Kang et al.: “Scientific Analysis of Formulation Theory of Chungpesagan-tang; In vitro Cytotoxicity of Cisplatin Combined with Chungpesagan-tang”, Natural Product Sciences, vol. 6(4), pp. 165-169, 2000.
[cited by applicant]
Kanzawa et al.: Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int. J. Cancer 71, 311-319,…
[cited by applicant]
Khoshyomn et al.: Synergistic Action of Genistein and Ciplatin on Growth Inhibition and Cytotoxicity of Human Medulloblastoma Cells. Pediatr Neurosurg. 33:123-31, 2000.
[cited by applicant]
Kinjo et al.: Novel santalin analogs from
[cited by applicant]
Klus et al.: Formation of polyhydroxylated isoflavones from the soybean seed isoflavones daidzein and glycitein by bacteria isolated from tempe. Arch Microbiol. 164(6):428-34, 1995 (Abstract Only in English).
[cited by applicant]
Kothari, et al. Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters: Atherosclerosis. (Shannon, Ireland) 128(1):59-66, 1997.
[cited by applicant]
Kulling et al.: Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J Agric Food Chem. 2001; 49(6):3024-33 (Abstract Only in English).
[cited by applicant]
Lasithiotakis et al.: Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. The Society for Investigative Dermatology. vol. 128:2013-2023 (2…
[cited by applicant]
Lawson, Estrogenic activity of some derivatives of isoflaven and isoflavanol. J Chem Soc. 4448-50, 1954 (Abstract Only in English).
[cited by applicant]
Lei et al.: Enhancement of Chemosensitivity and Programmed Cell death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells. Anticancer Res. 19:221-28, 1989.
[cited by applicant]
Leslie, Science,vol. 327, 2010, p. 1573.
[cited by applicant]
Li et al.: Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-KB in BxPC-3 Pancreatic Cancer Cell Line. Pancreas. (28)4:e90-5, 2004.
[cited by applicant]
Mani et al.: Isoflavones. I. Bromination of isoflavones. J Inst Chem. 1974; 46(Pt.3):61-5 (Abstract Only in English).
[cited by applicant]
Mani, et al, Isoflavones. III. Nitration of 7,8- and 6,7-dihydroxyisoflavones and their methyl ether. J Inst Chem. 1971; 43(6):234-40 (Abstract Only in English).
[cited by applicant]
Mansour et al.: Enhancement of Chemotherapeutic Efficacy by Combining Agents that Block IL-10 in CLL Cell Lines. New Jersey Medical School, UMDNJ, Newark, NJ, USA Blood. Nov. 16, 2002; 100(11) Abstract No. 4997. Print (…
[cited by applicant]
McDonnell et al.: Improvement in Efficacy of Chemoradiotherapy by Addition of and Antiangiogenic Agent in a Murine Tumor Model. J Surg Res. 2004; 116:19-23.
[cited by applicant]
Micheli et al.: “Coumestro, Plant Phenolics, and Synthetic Estrogens: a Correlation of Structure and Activity”, Journal of Medicinal and Pharmaceutical Chemistry, vol. 5, 1962, pp. 321-335.
[cited by applicant]
Modified Cyclodextrins: Scaffolds and Templates for Supramolecular Chemistry (Eds. Christopher J. Easton, Stephen F. Lincoln, Imperial College Press, London, UK, 1999).
[cited by applicant]
Montandon et al.: In-vitro versus in-vivo activities of new 5-lipoxygenase inhibitors with anti-inflammatory activity, Int J Tissue React. 1989; 11(3); 107-12 (Abstract Only in English).
[cited by applicant]
Nakata et al., C225 Antiepidermal Growth Factor Receptor Antibody Enhances the Efficacy of Docetaxel Chemoradiotherapy. Int J Radiation Oncology Biol Phys. 2004; 59(4): 1163-73.
[cited by applicant]
Navarro et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Reports 15:2705-2718 (2016).
[cited by applicant]
Nazir, et al. “Immunomodulatory Activity of Isoflavones Isolated from Iris Germananica (Iridacceae) on T-lymphocytes and Cytokines.” Phytotherapy Research. 2009.
[cited by applicant]
Neelam et al.: Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and diflouoromethylornithine (DFMO) in vitro against human colon cancer cells. Invest New Drugs. Aug. 1990; 8(3):263-8 (Abstract Only…
[cited by applicant]
O'Dwyer et al.: Antitumor Activity and Biochemical Effects of Aphidicolin Glycinate(NSC 303812) Alone and in Combination with Cisplatin in Vivo. Cancer Res. Feb. 1, 1994; 54:724-29.
[cited by applicant]
O'Neill et al.: Inducible Isoflavonoids from the Lima Bean, Phaseolus Lunatus. Phytochemistry. 1986; 25(6): 1315-22.
[cited by applicant]
PCT/AU2005/001435 International Search Report dated Dec. 21, 2005.
[cited by applicant]
PCT/AU2005/001436 International Search Report dated Dec. 21, 2005.
[cited by applicant]
PCT/US2011/058815 International Preliminary Report on Patentability dated May 7, 2013.
[cited by applicant]
PCT/US2011/058815 International Search Report and Written Opinion dated Mar. 12, 2012.
[cited by applicant]
PCT/US2011/058820 International Preliminary Report on Patentability dated May 8, 2013.
[cited by applicant]
PCT/US2011/058820 Search Report and Written Opinion dated Jun. 21, 2012.
[cited by applicant]
PCT/US2016/016008 International Preliminary Report on Patentability dated Aug. 8, 2017.
[cited by applicant]
PCT/US2016/016008 International Search Report and Written Opinion dated Apr. 19, 2016.
[cited by applicant]
Piha-Paul et al.: Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 5(7):1846-1855 (2014).
[cited by applicant]
Portlock, et al. (Lymphoma research Foundation, getting the Facts, Mar. 2007).
[cited by applicant]
Powles: A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial grown factor refractory clear cell renal cancer. European Journal of Cancer. 50(12):2057-2064 (2014).
[cited by applicant]
Rafi et al.: Modulation of bcl-2 and Cytotoxicity by Licochalcone-A, a Novel Estrogenic Flavonoid. Anticancer Res. 20:2653-58, 2000.
[cited by applicant]
Ravindranath et al.: Anticancer Therapeutic Potential of Soy Isoflavone, Genistein. Complementary and Alternative Approaches to Biomedicine, edited by Edwin L. Cooper and Nobuo Yamaguchi. Kluwer Academic/Plenum Publishe…
[cited by applicant]
Registration No. 1157-39-7, 4H-1-Benzopyran-4-one, 7-methoxy-3-(4-methoxyphenyl)-methyl-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 116703-40-3, 4H-1-Benzopyran-4-one, 2,3-dihydro-7,8-dimethoxy-3-(4-methoxyphenyl)-(9CI), Oct. 2, 1988.
[cited by applicant]
Registration No. 116703-49-2, 4H-1-Benzopyran-4-one, 2,3-dihydro-7,8-dihydroxy-3-(4-methoxyphenyl)-(9CI), Oct. 2, 1988.
[cited by applicant]
Registration No. 116718-51-5, 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-8-methyl-methyl-(9CI), Oct. 2, 1988.
[cited by applicant]
Registration No. 124093-18-1, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-(9CI), Dec. 1, 1989.
[cited by applicant]
Registration No. 129159-04-2, 4H-1-Benzopyran-4-one, 2,3-dihydro-3-(4-hydroxyphenyl)-(9CI), Aug. 31, 1990.
[cited by applicant]
Registration No. 129159-05-3, 4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-2,3-dihydro-(9CI), Aug. 31, 1990.
[cited by applicant]
Registration No. 13139-86-1, Magnesium, bromo(4-methoxyphenyl)-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 142050-44-0, 4H-1-Benzopyran-4-one, 7-hydroxy-3-[4-methoxy-3-(methoxy-t3)phenyl]-(9CI), Jun. 26, 1992.
[cited by applicant]
Registration No. 143358-24-1, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-methoxy-3-(4-methoxyphenyl)-(+)-(9CI), Sep. 9, 1992.
[cited by applicant]
Registration No. 143358-39-8, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-methoxy-3-(4-methoxyphenyl)-(-) (9CI), Sep. 9, 1992.
[cited by applicant]
Registration No. 15236-11-0, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-methoxy-3-(4-methoxyphenyl)-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 16750-63-3, Magnesium, bromo(2-methoxyphenyl)-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 201678-33-3, 4H-1-Benzopyran-4-one, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-7,8-dimethoxy-(9CI), Feb. 22, 1998.
[cited by applicant]
Registration No. 206257-38-7, 4H-1-Benzopyran-4-one, 2, 3-dihydro-3-(4-hydroxyphenyl)-7-methoxy-(9CI), Jun. 3, 1998.
[cited by applicant]
Registration No. 24160-14-3, 4H-1-Benzopyran-4-one, 3-(3,4-dimethoxyphenyl)-7-hydroxy-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 288267-24-3, 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-8-methyl-(9CI), Sep. 6, 2000.
[cited by applicant]
Registration No. 304892-19-1, 4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-(9CI), Nov. 29, 2000.
[cited by applicant]
Registration No. 36282-40-3, Magnesium, bromo(3-methoxyphenyl)-, Nov. 16, 1984.
[cited by applicant]
Registration No. 39604-72-3, 4H-1-Benzopyran-4-one, 2,3-dihydro-7methoxy-3-(4-methoxyphenyl)-8-methyl-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 4626-22-6, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-methoxyphenyl)-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 67492-31-3, 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 680195-83-9, 4H-1-Benzopyran-4-one, 2,3-dihydro-7,8-dihydroxy-3-(4-hydroxyphenyl)-(9CI), May 6, 2004.
[cited by applicant]
Registration No. 83206-83-1, 4H-1-Benzopyran-4-one, 3-(3,4-dimethoxyphenyl)-2,3-dihydro-7-hydroxy-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 85915-64-6, 2H-1-Benzopyran-7-ol, 4-[5-(3,4-dihydro-7-hydroxy-2-H-1-benzopyran-3-yl)-4-hydroxy-2-methoxypheny1]-3,4-dihydro-3-(2-hydroxy-4-methoxypheny1)-,[3S-[3α-4β(R*)]]-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 85915-66-8, 2H-1-Benzopyran, 4-[5-(3,4-dihydro-7-methoxy-2H-1-benzopyran-3-y1)-2,4-dimethoxypheny1]-3-(2,4-dimethoxypheny1)-3,4-dihydro-7-methoxy-, [3S-[3α4β(R*)]]-(9CI), Nov. 16, 1984.
[cited by applicant]
Registration No. 95307-73-6, 4H1-Benzopyran-4-one-2-d, 2,3-dihydro-2-d-7-hydroxy-3-(4-methoxyphenyl)-(9CI), Mar. 16, 1985.
[cited by applicant]
Registration No. 95457-39-9, 4H-1-Benzopyran-4-one-4-14C, 3-(3,4-dimethoxyphenyl)-7-hydroxy-(9CI), Mar. 23, 1985.
[cited by applicant]
Registration No. 95541-42-7, 1,3-Benzenediol, 4-[3,4-dihydro-3-(2-hydroxy-4-methoxypheny1)-7-methoxy-2H-1-benzopyran-4-yl]-,(3R-trans)-(9CI), Mar. 30, 1985.
[cited by applicant]
Registration No. 95541-43-8, 2H-Benzopyran, 3,4-bis(2,4-dimethoxyphenyl)-3,4-dihydro-7-methoxy-,(3R-trans)-(9CI), Mar. 30, 1985.
[cited by applicant]
Registration No. 95541-44-9, 1,3,5-Benzenetrio1,2-[3,4-dihydro-3-(2-hydroxy-4-methoxypheny1)-7-methoxy-2H-1-benzopyran-4-yl)-,(3R-trans)-(9CI) (1984).
[cited by applicant]
Registration No. 95541-45-0, 1,3,5-Benzenetrio1,2,4-bis[3,4-dihydro-3-(2-hydroxy-4-methoxypheny1)-7-methoxy-2H-1-benzopyran-4-yl]-,[3R-[3α,4β(3R*,4S″])-(9CI) (1984).
[cited by applicant]
Registration No. 95541-46-1, 2H-1-Benzopyran,3-(2,4-dimethoxyphyeny1)-3,4-dihydro-7-methoxy-4(2,4,6-trimethoxyphenyl)-,(3R-trans)-(9CI) (1984).
[cited by applicant]
Registration No. 95541-51-8, 2H-1-Benzopyran-7-ol,3-[3,4-dihydro-3-(2-hydroxy-4-methoxypheny1)-7-methoxy-2H-1-benzopyran-4-y1]-2-hydroxy-4-methoxypheny1]-3,4-dihydro-,[3R-3α,4β(S*)]-(9CI) (1984).
[cited by applicant]
Registration No. 95541-53-0, 2H-1-Benzopyran,4-[5(3,4-dihyrdro-7-methoxy-2H-1-benzopyran-3-y1)-2,4-dimethoxypheny1]-3-(2,4-dimethoxypheny1)-3,4-dihydro-7-methoxy-,[3R-[3α,4β(S*)]]-(9CI) (1984).
[cited by applicant]
Registration No. 95541-54-1, 2H-1-Benzopyran-7-ol,3-[-[4-dihydro-4-[4-hydroxy-5-(7-hydroxy-2H-1-benzopyran-3-y1)-2-methoxypheny1]-3-(2-hydroxy-4-methon/pheny1)-(3S-trans)-(9Cl) (1984).
[cited by applicant]
Registration No. 95541-57-4, 2H-1-Benzopyran,4-[2,4-dimethoxy-5-(7-methoxy-2H-1-benzopyran-3-yl)phenyl]-3-(2,4-dimethoxyphenyl)-3,4-dihydro-7-methoxy-,(3S-trans)-(9CI) (1984).
[cited by applicant]
Registration No. 95541-66-5, 2H-1-Benzopyran, 4-(2,4-dimethoxypheny1)-3,4-dihydro-7-methoxy-3-[4-methoxy-2-(methoxymethoxy)phenyl]-,(3R-trans)-(9Cl) (1984).
[cited by applicant]
Registration No. 95762-78-0, 2H-1-Benzopyran,4,4′-(2,4,6-trimethoxy-1,3-phenylene)bix[3-(2,4-dimethoxypheny1)-3,4-dihydro-7-methoxy-,[3R[3α,4β(3′R*,4'S*)]]-(9CI) (1984).
[cited by applicant]
Scambia et al.: Antiproliferative effect of silybin on gynaecological malignancies; synergism with cisplatin and doxorubicin. Eur J Cancer. May 1996; 32A(5):877-82 (Abstract Only in English).
[cited by applicant]
Scambia, G. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anti-Cancer Drugs Oct. 1990; 1(1):45-8 (Abstract Only in English).
[cited by applicant]
Sepulveda-Boza et al.: The preparation of new isoflavones, Synthetic Communications. 2001; 3(12):1933-40.
[cited by applicant]
Stella, Expert Opinion on Therapeutic Patents, Prodrugs as therapeutics, vol. 14, No. 3, pp. 277-280 (2004).
[cited by applicant]
Szlosarek et al.: Tumour necrosis factor a: a potential target for the therapy of solid tumours. The Lancet Oncology. Sep. 2003; 4:565-73.
[cited by applicant]
Tamura et al.: Genistein Enhances the Cisplatin-Induced Inhibition of Cell Growth and Apoptosis in Human Malignant Melanoma Cells. Pigment Cell Res. 2003; 16:470-76 (Abstract Only in English).
[cited by applicant]
Teo et al.: Synthesis of 3-(p-fluorophenyl)-4-arylchrom-3-enes as selective ligands for antiestrogen-binding sites. J Chem Res. Synopses. 1990; 1:4-5 (Abstract Only in English).
[cited by applicant]
Teo et al.: Synthesis of arylchromenes and arylchromans. Bulletin of the Singapore National Institute of Chemistry. 1994; 22:69-74 (Abstract Only in English).
[cited by applicant]
Therasse et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst., 92 (3): 205-216 (2000).
[cited by applicant]
Therasse et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute…
[cited by applicant]
Todorov et al.: Role of a proteolysis-inducing factor(PIF) in a cachexia induced by a human melanoma(G361). Br J Cancer. 1999; 80(11):1734-37.
[cited by applicant]
Tubiana. The combination of radiotherapy and chemotherapy: a review. Int J Radiat Biol 55(4):497-511 (1989).
[cited by applicant]
U.S. Appl. No. 14/186,940 Office Action mailed Nov. 21, 2014.
[cited by applicant]
U.S. Appl. No. 11/230,726 Office Action dated Aug. 10, 2007.
[cited by applicant]
U.S. Appl. No. 11/230,726 Office Action dated Jan. 22, 2007.
[cited by applicant]
U.S. Appl. No. 11/230,726 Office Action dated Mar. 4, 2008.
[cited by applicant]
U.S. Appl. No. 11/230,726 Office Action dated Oct. 28, 2008.
[cited by applicant]
U.S. Appl. No. 12/551,277 Office Action dated Jan. 6, 2011.
[cited by applicant]
U.S. Appl. No. 12/551,277 Office Action dated May 28, 2010.
[cited by applicant]
U.S. Appl. No. 13/293,947 Office Action dated Jul. 20, 2012.
[cited by applicant]
U.S. Appl. No. 13/293,947 Office Action dated May 24, 2013.
[cited by applicant]
U.S. Appl. No. 13/293,947 Office Action dated Nov. 8, 2012.
[cited by applicant]
U.S. Appl. No. 14/186,940 Office Action dated Aug. 6, 2014.
[cited by applicant]
U.S. Appl. No. 13/891,975 Office Action dated Apr. 23, 2014.
[cited by applicant]
U.S. Appl. No. 11/230,505 Office Action dated Dec. 17, 2009.
[cited by applicant]
U.S. Appl. No. 11/230,505 Office Action dated Jun. 9, 2008.
[cited by applicant]
U.S. Appl. No. 11/230,505 Office Action dated Mar. 12, 2009.
[cited by applicant]
U.S. Appl. No. 11/230,505 Office Action dated Sep. 4, 2007.
[cited by applicant]
“U.S. Appl. No. 13/061,112 Final Office Action mailed May 28, 2015”.
[cited by applicant]
U.S. Appl. No. 13/415,697 Office Action dated Jul. 6, 2012.
[cited by applicant]
U.S. Appl. No. 13/881,599 Office Action dated Apr. 9, 2015.
[cited by applicant]
U.S. Appl. No. 13/881,599 Office Action dated Aug. 18, 2016.
[cited by applicant]
U.S. Appl. No. 13/881,599 Office Action dated Sep. 18, 2014.
[cited by applicant]
U.S. Appl. No. 13/881,609 Office Action dated Apr. 10, 2015.
[cited by applicant]
U.S. Appl. No. 13/881,609 Office Action dated Aug. 7, 2015.
[cited by applicant]
U.S. Appl. No. 13/881,609 Office Action dated May 16, 2016.
[cited by applicant]
U.S. Appl. No. 14/922,472 Office Action dated Sep. 26, 2016.
[cited by applicant]
U.S. Appl. No. 15/175,386 Office Action dated May 10, 2018.
[cited by applicant]
U.S. Appl. No. 15/175,386 Office Action dated Oct. 6, 2017.
[cited by applicant]
U.S. Appl. No. 15/456,182 Office Action dated Nov. 20, 2017.
[cited by applicant]
U.S. Appl. No. 15/546,900 Office Action dated Sep. 26, 2019.
[cited by applicant]
U.S. Appl. No. 15/622,569 Office Action dated Sep. 7, 2017.
[cited by applicant]
U.S. Appl. No. 15/961,259 Office Action dated Sep. 5, 2018.
[cited by applicant]
U.S. Appl. No. 16/129,589 Final Office Action dated Nov. 7, 2019.
[cited by applicant]
U.S. Appl. No. 16/129,589 Office Action dated Apr. 18, 2019.
[cited by applicant]
U.S. Appl. No. 16/129,589 Office Action dated Mar. 19, 2020.
[cited by applicant]
U.S. Appl. No. 16/444,981 Final Office Action dated Aug. 20, 2020.
[cited by applicant]
U.S. Appl. No. 16/444,981 Office Action dated Mar. 3, 2020.
[cited by applicant]
Varady, J. The flavonoids of Podocarpus spicatus. I. Structure of podospicatin. Synthesis of podospicatin mono-, di-, and trimethyl ethers. Periodica Polytech. 1963; 7(4):241-58 (Abstract Only in English).
[cited by applicant]
Verma et al., Smooth Conversion of 3,4-Diarylcoumarins and 3,4,5-Triaryl-2(5H)-furanones to 2H-Chromene and 2,5-Dihydrofuran Derivatives with Dimethyl Sulfide-Borane Complex. Synthesis. 1988; 1:68-70.
[cited by applicant]
Voss, C. et al., New isoflavonoids as inhibitors of porcine 5-lipoxygenase. Biochem Pharmacol. 1992; 44(1):157-62 (Abstract Only in English).
[cited by applicant]
Waud et al.: Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia, Cancer Chemotherapy and Pharmacology. 1991; 27 (6):456-63 (Abstract Only in English).
[cited by applicant]
Weidenborner et al.: Control of storage fungi of the genus
[cited by applicant]
Widder et al. Section III: Prodrugs Kinetics. Method in Enzymology. 112:309-396 (1985).
[cited by applicant]
Wolfbeis et al.: The Absorption and Fluorescence of Isoflavones and the Effect of Shift Reagents. Z Naturforsch. 39b:238-43, 1984.
[cited by applicant]
Zyner et al.: Platinum(II) and palladium(II) N,0-Chelates with substituted flavanone containing ligangs. Acta Pol Pharm. 1999; 56(2): 159-67.
[cited by applicant]
Zyner et al.: Pt(II) and Pt(II) complexes of 3-aminoflavone: In vitro and in vivo evaluation. Pharmazie. 1999; 54(12):945-46.
[cited by applicant]
U.S. Appl. No. 17/023,681 Office Action dated Nov. 18, 2021.
[cited by applicant]
U.S. Appl. No. 17/193,335 Office Action dated Sep. 15, 2022.
[cited by applicant]
U.S. Appl. No. 18/340,308 Office Action dated Jul. 3, 2024.
[cited by applicant]